Alto Neuroscience (Alto Neuroscience) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Alto Neuroscience's Free Cash Flow for the three months ended in Mar. 2024 was $-11.21 Mil. Alto Neuroscience's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Alto Neuroscience's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Alto Neuroscience's current FCF Yield % is -6.65%.

The historical rank and industry rank for Alto Neuroscience's FCF Margin % or its related term are showing as below:

During the past 3 years, the highest FCF Margin % of Alto Neuroscience was -4734.29%. The lowest was -4734.29%. And the median was -4734.29%.

ANRO's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -144.01
* Ranked among companies with meaningful FCF Margin % only.

Alto Neuroscience FCF Margin % Historical Data

The historical data trend for Alto Neuroscience's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience FCF Margin % Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

FCF Margin %

-4,734.29

Alto Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Alto Neuroscience's FCF Margin %

For the Biotechnology subindustry, Alto Neuroscience's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alto Neuroscience's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's FCF Margin % falls into.

Alto Neuroscience FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Alto Neuroscience's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-33.918	/	0
	=	%

Alto Neuroscience's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-11.207	/	0
	=	%

Alto Neuroscience FCF Margin % Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024